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Cranial nerve involvement in Charcot-Marie-T ooth disease (CMT) is rare, though there are a number of CMT
syndromes in which vocal cord paralysis is a characteristic feature. CMT disease due to mutations in the gan-
glioside-induced differentiation-associated protein 1 gene (GDAP1) h a sb e e nr e p o r t e dt ob ea s s o c i a t e dw i t hv o c a l
cord and diaphragmatic palsy. In order to address the prevalence of these complications in patients with GDAP1
mutations we evaluated vocal cord and respiratory function in nine patients from eight unrelated families with
this disorder.Hoarseness of the voice and inability to speak loudly were reported by eight patients and one had
associated symptoms of respiratory insufficiency. Patients were investigated by means of peripheral and phrenic
nerve conduction studies, flexible laryngoscopy, pulmonary function studies and polysomnography. Nerve con-
duction velocities and pathological studies were compatible with axonal CMT (CMT2). Flexible laryngoscopy
showed left vocal cord palsy in four cases, bilateral cord palsies in four cases and was normal in one case.
Restrictive respiratory dysfunction was seen in the eight patients with vocal cord paresis who were all chair-
bound. These eight had confirmed phrenic nerve dysfunction on neurophysiology evaluation. The patient with
normal vocal cord and pulmonary function had a less severe clinical course.This study shows that CMT patients
with GDAP1 mutations develop severe disability due to weakness of limb muscles and that laryngeal and respira-
tory muscle involvement occurs late in the disease process when significant proximal upper limb weakness has
developed.The early and predominant involvement of the left vocal cord innervated by the longer left recurrent
laryngeal nerve suggests a length dependent pattern of nerve degeneration. In GDAP1 neuropathy, respiratory
function should be thoroughly investigated because life expectancy can be compromised due to respiratory
failure.
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Introduction
The peroneal muscular atrophy syndrome or Charcot-
Marie-Tooth disease (CMT) is divided into several groups
according to clinical, electrophysiological and nerve biopsy
findings: (i) CMT1 showing a median nerve motor
conduction velocity (MCV) of 538m/s and nerve fibre
demyelination with proliferation of Schwann cells forming
onion bulbs; (ii) CMT2 with normal or near normal
conduction velocities and pathological signs of axonal
degeneration and regeneration; (iii) an intermediate type
(CMT-I) is now accepted in which MCV lies between 30
and 40m/s and nerve pathology shows axonal and
demyelinating features or it is undefined; and (iv) distal
hereditary motor neuronopathy (DHMN), also known as
distal spinal muscular atrophy or spinal CMT, in which
motor and sensory nerve conduction velocities are normal,
and electromyography shows features of neurogenic atrophy
with sparing of sensory nerves (Dyck and Lambert, 1968a,
b; Harding and Thomas, 1980; Houlden and Reilly, 2006).
Inheritance can be autosomal dominant (AD), autosomal
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 recessive (AR) and X-linked. Molecular studies have shown
extensive genetic heterogeneity in CMT neuropathies, so
each of the main types are subdivided according to the
correspondent genes or loci, being nominated either in
alphabetical tags (A/Z) or genes names. In this way, AD
CMT1 contains five gene-related subgroups (PMP22, MPZ,
LITAF, EGR2 and NEFL), and AD CMT2 integrates at least
six genes (MFN2, RAB7, GARS, NEFL, HSP27 and HSP22).
AR demyelinating CMT, more often known as CMT4,
contains 10 gene-subgroups (EGR2, GDAP1, SH3TC2,
MTMR2, MTMR13, NDRG1, PRX, FGD4, FIG4 and
CTDP1), and AR CMT2 has two recognized genes
(LMNA and GDAP1). The intermediate group is caused
by a limited number of distinct gene mutations (DNM2,
YARS and NEFL). The best known X-linked form (CMTX)
is due to mutations of GJB1 gene. DHMN is divided by
clinical criteria into seven types, four of them having
autosomal dominant inheritance (DHMN types I, II, V and
VII); all types, except DHMN-I, have mapped genetic loci
and some of them like DHMSN VII is also subdivided
(Irobi et al., 2006). The same gene can manifest different
phenotypes thus increasing complexity in CMT
classification.
Vocal cord palsy and diaphragmatic dysfunction are
infrequent and are not specific to any one type of CMT. It
is a feature of axonal CMT2C (MIM 606071), linked to
chromosome 12q23-24 (Klein et al., 2003), of DHMN type
VII mapping to chromosome 2q14 (DHMN VIIA; MIM
158580; McEntagart et al., 2001), of DHMN type VIIB
(MIM 607641) associated with dynactin 1 (DCTN1)
mutation (Puls et al., 2003), and of early onset ARCMT2
or CMT4A (MIM 214400) owing to mutations in the
ganglioside differentiating associated protein 1 gene (GDAP1)
(Sevilla et al., 2003).
GDAP1 related to CMT has been reported in families
affected with either demyelinating CMT (CMT4A, MIM
214400) (Baxter et al., 2002) or axonal CMT (ARCMT2,
MIM 606598) diseases (Cuesta et al., 2002). In both types
onset occurs in early infancy with distal limb weakness,
progressing proximally and causing severe disability.
Peripheral motor nerve conduction velocity (MNCV)
cannot be measured in many cases because of the absence
of muscle response due to distal atrophy, but latencies to
proximal muscles are within the normal range. Inherited
neuropathies associated with mutations in the GDAP1 gene
show a complex phenotypic spectrum. Although CMT4A
usually refers to demyelinating ARCMT forms, it has also
been used on several occasions in which the primary
phenotype was found to be axonal. According to the
OMIM database axonal forms of GDAP1 associated disease
are referred to either as CMT2K (MIM 607831) or CMT2
plus vocal cord paresis (MIM 607706). Most GDAP1
mutations show autosomal recessive inheritance but in
some families the disease segregates as an autosomal
dominant trait (Claramunt et al., 2005; Chung et al., 2008).
Vocal cord palsy and diaphragmatic dysfunction can
cause airway compromise and respiratory failure. We have
studied the frequency and characteristics of vocal cord and
respiratory function in patients with CMT and mutations in
GDAP1 gene.
Patients and Methods
Families
We performed a systematic search for GDAP1 mutations in all
index cases of our CMT series in which mutations for PMP22,
MPZ or GJB1 genes had been excluded, independently of the
observed phenotype. There were 11 patients from 8 families with
GDAP1 mutations to whom it was offered to participate in the
study, but two of them refused. The pedigrees are displayed in
Fig. 1. All parents were unaffected and there was only one
consanguineous union. All the patients came from Valencian
Community and have been submitted to regular follow-up for a
mean of 15.7 years (range 2–37 years) except one patient who
came from other geographic region and was specifically investi-
gated for this study. The neuropathic symptoms were evaluated by
two of the authors (T.S. and J.J.V.) and the electrophysiological
studies were all performed by the same person (M.J.C.).
The patients were classified using the Harding and Thomas
criteria (1980) as CMT1 if the conduction velocity of the median
nerve was below 38m/s or as CMT2 if the velocity was higher.
Patients with CMAP of very low amplitude or absent were
classified according to the motor conduction velocity from the
axillary nerve or, when possible, by sural nerve biopsy.
Clinical study
All probands and individuals at-risk of having inherited the
disease living in Valencia were examined. In the family living
outside Valencia only the proband was examined. Evaluation of
mutation carriers revealed no clinical manifestations. Assessment
included: strength, muscle atrophy, sensory loss, reflexes, foot
deformities, scoliosis, changes in the voice and alterations of other
cranial nerves. Muscle strength was assessed using the standard
Medical Research Council (MRC) scale. CMT neuropathy score
(CMTNS) was used to determine neurological impairment (Shy
et al., 2005). Patients could be divided into three categories: mild
(CMTNS410 points), moderate (CMTNS 11–20) and severe
(CMTNS 21–36). A screen for voice disturbances, stridor,
dysphagia, dyspnoea at rest or after exercise and the presence of
snoring during sleep was carried out by questionnaire.
Electrophysiological study
Electrophysiological studies were performed in all the patients and
at-risk members of seven families. In family LF250 the study was
only performed on the proband (II-5). Nerve conduction studies
(NCS) were tested with surface electrodes. Amplitudes of
compound muscle action potentials (CMAPs), distal latency
(DL) and conduction velocity from median, ulnar, peroneal,
tibial and axillary nerves were recorded using conventional
methods. Futhermore, motor nerve conduction studies of more
proximal upper limb muscles like palmaris longus muscle for
the median nerve and flexor carpi ulnaris for the ulnar nerve were
also tested. CMAP and DL from the diaphragm muscle were
recorded by phrenic nerve stimulation in the neck (Bolton, 1993).
3052 Brain (2008),131, 3051^3061 T . Sevilla et al.
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 Recordings of sensory nerve action potentials (SNAPs) from
median and ulnar nerves were performed orthodromically while
sural nerve was tested antidromically. Concentric needle electro-
myography was performed in the proximal and distal muscles of
the upper and lower limbs.
Flexible laryngoscopy and pulmonary function
tests
The laryngeal study was performed by an ENT specialist using a
flexible fibreoptic laryngoscope. The position of the cords was
evaluated during inspiration and phonation. The results were
filmed and reviewed. The normal separation of the vocal cords
during respiration is of  13.5mm.
Pulmonary function tests including spirometry, static lung
volumes, maximum inspiratory and expiratory pressures and
arterial blood gases breathing air, postero–anterior chest X-ray and
respiratory polygraphy were performed in all patients.
Spirometry was performed using Collins G II Plus spirometer
(Collins, MA, USA) following the recommendations of the
American Thoracic Society and using their references values
(Gardner et al., 1987). The lung volumes were measured using a
Collins BO-XII plethysmograph, using the reference values
recommended in the official guideline of the European
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Fig. 1 Pedigrees of the families reported in the present study.
Vocal cord paresis and GDAP1neuropathy Brain (2008),131, 3051^3061 3053
b
y
 
g
u
e
s
t
 
o
n
 
N
o
v
e
m
b
e
r
 
7
,
 
2
0
1
4
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 Community (Quanjer Ph, 1983). The maximum inspiratory
pressure was measured from the residual volume and the maximum
expiratory volume from the total lung capacity using a Siebelmed
163 electromanometer (Siebel, Barcelona, Spain) connected to and
x-y Servogor 731 recorder (Goetz Metrawatt, Nuremberg,
Germany). The reference values used were those of the Spanish
Society of Pneumology and Thoracic Surgery (SEPAR) (Casan et al.,
1989). All values were given as the absolute figure and as a
percentage of the predicted value. The arterial blood gas sample was
taken by puncture of the radial artery and introduction of the blood
sample into the ABL700 gas analyser (Radiometer, Copenhagen,
Denmark). Respiratory polygraphy was performed at the patient’s
home during the hours of sleep, recording the heart rate, oxygen
saturation and number of apnoeas and hypopnoeas per hour, also
enabling us to differentiate between central and obstructive apnoea.
Episodes of apnoea were defined as the complete cessation of airflow
for410s. Hypopnoea refers to a 50% reduction in the airflow or a
30–50% reduction of the flow associated with microarousals or
desaturation 53%, with a duration of 410s in both cases. The
instrument used was the Somte Polygraph (Compumedics,
Abbotsford, Australia).
Pathological study
Biopsy of the sural nerve was performed in four patients and was
studied by light and electron microscopy using standard methods
as previously reported in detail (Sevilla et al., 2003).
Mutation analysis
Blood samples were drawn from the patients and relatives after
informed consent and in accordance with the Helsinki declaration.
DNA was extracted using conventional procedures. All the
probands who had been shown to be negative for CMT1A
duplication (17p11.2) and point mutations in PMP22, MPZ and
GJB1 genes were screened for mutations in the GDAP1 gene
(NM_018972). PCR amplification of the six exons of the GDAP1
gene was performed using primers previously described (Cuesta
et al., 2002; Claramunt et al., 2005). PCR products were screened
for sequence variants by dHPLC on a WAVE DNA Fragment
Analysis System, Model 3500HT (Transgenomic). The running
conditions for each amplicon were determined by the Navigator
TM
Software version 1.6.4. based on the DNA sequence. In order to
detect homozygous variants, PCR products from patients were
mixed with the corresponding PCR fragment from a normal
control. Elution peaks were analysed with the Navigator
TM
Software and fragments displaying abnormal elution peaks were
analysed by direct sequencing on an automated sequencer (ABI
PRISM-3130XL, Applied Biosystems).
Results
Clinical characteristics and
electrophysiological studies
The study included nine patients (6 male and 3 female)
with ages ranging from 16 to 49 years (median 34). Clinical
data are summarized in Table 1. Most of the patients had
difficulty walking from early childhood. Additionally, five
patients presented with congenital hypotonia and four had
delay in their motor development. The most consistent
clinical abnormality was distal muscle wasting and weakness
of upper and lower limbs. The upper limbs were never
involved to a greater extent than the lower. All the patients,
except LF250 II-5, presented with proximal upper limb
weakness. Sensory abnormalities and areflexia was found in
all the patients. Seven patients were chairbound in the first
and second decade. Two patients (LF80 II-1 and LF262
II-4), presented with joint laxity and were obese. One
patient presented bilateral facial weakness (LF80 II-1).
The affected members of family LF249 had been followed
up in our hospital since 1971 and the clinical findings have
been reported previously (Sevilla et al., 2003). A description
of the evolution of their symptoms is given in order to
emphasize the severity of the disease. Patient LF249 II-4
had severe proximal upper limb weakness, needing help for
feeding; he suffered from HIV acquired immunodeficiency
syndrome and died of pneumonia at 41 years old. Patient
LF249 II-6 had a sudden death while asleep at 40 years
without warning. Patient LF249 II-2 complained of
defecatory urgency and intermittent episodes of faecal
incontinence over the past 5 years; coloproctologic
examination demonstrated a significant reduction in anal
pressure during voluntary contractions with preservation of
the excitatory rectoanal reflex. Internal and external anal
sphincters atrophy was detected by ultrasounds, and
pudendal nerves EMG study revealed abnormal latencies.
The electrophysiological data are shown in Table 2. All
patients had been subject to serial electrophysiological
studies and three of them (LF135 II-1, LF80 II-1 and LF107
II-1) to an initial testing at a very early age. In five patients
(LF249 II-2, LF20 II-4, LF80 II-1, LF262 II-4 and LF14 II-7)
it was not possible to obtain a distal motor response. The
study on patient LF135 II-1 was performed at the age of
two showing a conduction velocity of 35m/s. The case was
classified as axonal CMT taking into account the fact that
the myelination at this age is not fully mature and also the
results of the sural nerve biopsy. The latency of the axillary
nerve was normal in all patients. The studies performed
before 3 years of age showed that the amplitude of the
CMAPs was very low in two cases and absent in one. The
subsequent serial studies revealed a fall in the potential
amplitude or an absent response a few years later. Peroneal
MNCV can still be detected in patient LF250 II-5at 45 years
of age, with almost normal values in the upper limbs. This
patient presented a much milder clinical course. The SNAP,
although severely abnormal in the majority of the cases,
persisted for longer than the CMAP. These findings are
compatible with an axonal form of CMT. Phrenic nerve
responses were abnormal in all patients except in LF250
II-5 (Table 2).
Evaluation of laryngeal and respiratory
function
Laryngeal symptoms and indirect laryngoscopy
The symptoms related to laryngeal and respiratory function
are listed in Table 3. Six patients reported changes in their
3054 Brain (2008),131, 3051^3061 T . Sevilla et al.
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 Table 1 Clinical findings
Family/case
LF249 (II-2) LF20 (II-3) LF20 (II-4) LF135 (II-1) LF80 (II-1) LF262 (II-4) LF107 (II-1) LF14 (II-7) LF250 (II-5)
Age (years)/sex 49/M 42/M 36/M 22/F 16/M 38/F 16/F 47/M 45/M
A g eo fw a l k i n g 1 2m o n t h s D e l a y e d 1 8m o n t h s 1 2m o n t h s 1 8m o n t h s 1 8m o n t h s 1 2m o n t h s 1 2m o n t h s 1 2m o n t h s
Age of onset 18 months 51y ea r 51y ear 1 8mont hs 51y ear 51year 7 months 12 months 8 years
Hypotonia
at birth
No Yes Yes Y es Y es Yes No No No
Proximal UL
weakness
+ +++ + + + ++N o
Distal UL
weakness
+++ +++ +++ +++ +++ +++ +++ +++ ++
Proximal LL
weakness
++ ++ ++ ++ ++ ++ ++ ++ No
Distal LL
weakness
+++ +++ +++ +++ +++ +++ +++ +++ +++
Sensory loss
in UL
P, V, T P, V, T P, V, T P, V, T P, V, T P, V, T P, V, T P, V, T P
Sensory loss
in LL
All All All All All All All All P,V
Reflexes Absent Absent Absent Absent Absent Absent Absent Absent Absent
S c o l i o s i s M i l d N oN oN o N o N o N oN oN o
Functional
disability UL
Claw-hand Claw-hand Claw-hand Claw-hand Claw-hand Claw-hand Claw-hand Claw-hand Moderate
Functional
disability LL
W-B,
13 years
W-B,
9y e a r s
W-B,
10 years
W-B,
12 years
W-B,
14 years
W-B,
18 years
W-B,
12 years
W-B,
38 years
AFO
C M T N S 3 1 3 13 13 0 3 03 0 2 93 01 9
Mutation p.Q163X/
p.S194X
p.Q163X/
p.T288NfsX3
p.Q163X/
p.T288NfsX3
p.Q163X/
p.Q163X
p.T288NfsX3/
p.T288NfsX3
p.P59AfsX4/
c.311-1G4A
p.S194X/
p.T288NfsX3
p.S194X/
p.T288NfsX3
p.R282C/
p.R282C
Biopsy/age 22 years 19 years ND 30months ND 32 years ND ND ND
Muscleweaknessinupperlimbs(UL)orlowerlimbs(LL):+=strength4/5onMCRscale;++=strength54/5onMedicalResearchCouncilscale;
+++=completeparalysis.Sensorychanges:P,V,T=decreasespinprick,vibrationandtouch;all=absentpinprick,vibration,touchandposition
sense.ND=notdone;CMTNS=CMTneuropathyscore,AFO=ankle-footorthosis,W-B=wheelchairbound.
Table 2 Electrophysiological data
Patient/age at study Axillary Phrenic Median Ulnar Peroneal
CMAP DL CMAP DL CMAP DL MCV SCV CSNAP CMAP DL MCV SCV CSNAP CMAP DL MCV
LF249 (II-2)/39 years 11.7 3.2 0.1 6.5 NR 53
a 1.3 NR 50
a 1.9
LF20 (II-3)/27 years 4.5 3.2 0.1 4.8 0.2 5.3 37 NR NR NR
LF20 (II-4)/26 years 4.8 2.7 0.1 5.1 NR NR NR NR
LF135 (II-1)/2 years NP NP 3 2.5 35 NP NR
LF135 (II-1)/5 years NP NP 0.7 3.7 26 33 1 2 3.1 32 NP NR
LF135 (II-1)/17 years 11.4 4.6 0.3 7.2 NR NR NR NR NR
LF80 (II-1)/2 years NP NP NR NP NR NP NR
LF80 (II-1)/8 years 11.2 2.5 NR
b 0.6
c 4.2 70 42 1.8 NR 54
a 2.1 NR
F262 (II-4)/31years 10.4 4.8 0.1 6.8 0.3
c 55 3 3 61 . 1 N R 5 3
a 1.5 NR
LF107 (II-1)/3 years NP NP 0.4 3 46 41 3.9 2.2 2.4 54 NP 0.2 4.6
LF107 (II-1)/11 years 7.8 4 0.2 6.5 0.6
c 44 8 N R N R 5 2
a 1.7 NR
LF14 (II-7)/45 years 6.3 3.1 0.1 7 .5 NR NR NR NR NR
LF250 (II-5)/45 years 14.4 3.4 1 7 .2 6.3 3.5 50 34 1.3 8.1 2.7 58 34 1.6 0.3 6 40
aMixed;
bS t u d yw a sd o n ea t1 6y e a r so l d ;
cFlex.carp.radialis; (axilla-elbow) distal potential not recorded; Normal values=axillary
CMAP47m v ,D L55.3; Phrenic = CMAP40.3 mV, DL57 .9ms; MCVs=median and ulnar nerves451m/s, peroneal 444m/s;
CMAP=median49m v ,ul nar47.7 mv, p ero neal 45.9 mv; DL = median54.1, ulnar53.3, peroneal55.5; SCVs=median andulnar443m/s;
CSNAP=median416.5 mv; ulnar46.8mv.CMAP=compound muscle action potential; DL=distal motor latency; MCV=motor nerve
conduction velocity; SCV=sensory conduction velocity; CSNAP=compound sensory nerve action potential; NP=not performed;
N R=noresponse.
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 voice since adolescence, being particularly noticeable on
singing or shouting. Initially, the dysphonia was fluctuating
in two cases (LF249 II-2 and LF107 II-1), becoming
persistent in one of them (LF249 II-2) and improving
subjectively in the other during the past year (LF107 II-1).
One patient (LF262 II-4) has not noticed changes in her
voice, although she admits always having a shrill voice and
being unable to sing or shout since adolescence. Another
patient (LF14 II-7) states that his voice problems began at
45 years of age with episodes of hoarseness that lasted for
about 3 days and persisted for 2 months. None of the
patients reported stridor, difficulty expectorating secretions
or problems when sleeping. One patient (LF249 II-2) has
had occasional episodes of choking when drinking in recent
years, and has to pause frequently to catch his breath when
speaking. Two patients suffer occasional aspiration (LF249
II-2 and LF262 II-4).
The glottis opens to permit respiration and is closed
during phonation. Flexible laryngoscopy showed paresis of
both vocal cords in four patients and paresis of the left
vocal cord in other four (Table 3 and Fig. 2). The paralysed
cords were in a paramedian position (partial abduction)
during inspiration. In patient LF249 II-2 only minimal
movements of adduction were observed during phonation
(Fig. 2B). During phonation, vocal cords in patients with
bilateral paralysis were not fully adducted leaving a gap,
Table 3 Laryngeal and pulmonary function test findings
Family/case
LF249 (II-2) LF20 (II-3) LF20
(II-4)
LF135 (II-1) LF80
(II-1)
LF262 (II-4) LF107 (II-1) LF14
(II-7)
LF250 (II-5)
Age 49 42 36 22 16 38 16 47 45
Sex M M M F M F F M M
Hoar seness Yes/14 Yes/14 Yes/15 Yes/15 Yes/13 Yes/ 20 Yes/12 Yes/45 No
Dyspnoea No No No No No Yes No No No
Exercise intolerance Yes No No No No Y es No Y es No
Dysphagia/choking Fluids No No No No No No No No
Shortness of breath No No No No No Y es No No No
Snoring Yes ? No No Yes Yes No No No
VC palsy Both Both Both Left Left Left Left Both No
V Cp o s i t i o ni n s p i r a t i o n M e d i a nb o t hP Mb o t h P Mb o t h P Mb o t h P Ml e f t P Ml e f t P Ml e f t P Mb o t h A b d u ct e d
FVC (l/m) predicted 2.5 (71%) 2 (40%) 2.8 (55%) 2.4 (63%) 2.6 (50%) 1.2 (38%) 2.5 (75%) 2.8 (61%) 4.5 (95%)
TLC (l/m) 3.6 (62%) 2.8 (42%) 4.2 (63%) 3 (59%) 3.4 (51%) 1.9 (45%) 3.3 (73%) 5 (70%) 6.4 (91%)
FRC (l/m) 1.8 (60%) 1 (33%) 2.3 (70%) 1.5 (55%) 1.5 (45%) 1.9 (45%) 1.5 (71%) 3.2 (95%) 3.5 (102%)
RV (l/m) 0.8 (44%) 0.7 (41%) 1.3 (74%) 0.6 (43%) 0.7 (48%) 0.6 (45%) 0.6 (60%) 2 (100%) 1.8 (85%)
MIP 72.7 (66%) 65 (52%) 122 (111%) 100 (87%) 80 (75%) 61 (53%) 92 (87%) 116 (93%) 61 (56%)
MEP 72 (93%) 107 (51%) 114 (79%) 98 (103%) 80 (90%) 66 (78%) 82 (62%) 120 (59%) 175 (124%)
PSG Abnormal Normal Normal Normal Normal Abnormal Normal Normal ND
Chest X-ray/ elevation diaphragm Left side Both sides Left side Left side Both sides Both sides Right side Left side Normal
M=male;F=female;V C=vocalcord ;PM=paramed ian ;TL C=totall ungcapacity;FR C=funct ionalresid ualcapacity;R V=resid ualvol ume;
l/m=litres/minute; MEP=maximal expiratory pressure; MIP=maximal inspiratory pressure; PSG=polysomnography; ND=not done.
Fig. 2 GDAP1neuropathy with vocal cord paralysis demonstrated by flexible indirect laryngoscopy. (A) A16-year-old man (LF80 II-1) with
paralysed left vocal cords. (B and C) A 49-year-old man (LF249 II-2) with bilateral vocal cord paralysis and atrophy. Note lack of complete
glottis closure during vocal cord adduction (B); vocal cords lie near the midline during abduction (C) due to fibrotic contracture and
atrophy.
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 which was not observed in three of the patients with a
unilateral alteration and was minimal in the other. Vocal
cords were atrophic in those patients with a longer history
of dysphonia. Flexible laryngoscopy had been performed
previously in two of the patients with bilateral paralysis
(LF20 II-3 and LF14 II-7), and revealed paresis of left vocal
cord. Pharyngeal movement was also very poor in patients
with bilateral vocal cord paralysis.
Symptoms and pulmonary function tests
None of the patients spontaneously complained of respira-
tory symptoms, except for one patient (LF262 II-4) who is on
non-invasive ventilation since 2005 for this reason. On direct
questioning, three patients reported dyspnoea on exertion,
two on speaking and one when practising yoga (Table 3); the
remainder of the patients did not perform exercise except for
one who regularly went swimming. Three patients snored
(LF262 II-4, LF249 II-2 and LF14 II-7). None of the patients
presented significant malformations of the thoracic cage; one
had a mild degree of scoliosis. Chest X-ray revealed elevation
of the diaphragm in eight patients and was normal in one
patient (Table 3); this elevation was unilateral in five cases
and bilateral in three. Table 3 shows the spirometry values,
volumes and maximum inspiratory and expiratory pressures.
All the patients except one presented a restrictive functional
alteration that varied from mild (75% of the predicted value)
to very severe (38% of the predicted value). Serial pulmonary
function studies have been performed in three patients (LF20
II-3, LF14 II-7 and LF262 II-4) since 2005, finding a
progressive decrease in the forced vital capacity (FVC). The
maximum inspiratory pressure (MIP), as an index of muscle
strength, was moderately reduced (575% of the predicted
value) in four cases and was normal in the other patients.
Arterial blood gases showed gas exchange within the normal
range in all patients. Respiratory polygraphy was abnormal in
two patients (Table 3), who presented an apnoea/hypopnoea
index (number of episodes of apnoea plus hypopnoea per
hour of sleep),415 (normal516).
Pathological results
Sural nerve samples were obtained from several patients at
differing ages (LF135 II-1: 30 months; LF20 II-3: 19 years;
LF249 II-2: 22 years; LF262 II-4: 32 years) thus showing the
pathological progression of the neuropathy over time. The
most outstanding finding is a progressive depletion of
myelinated fibres (myelinated fibre density in LF135 II-1:
8700/mm
2; LF20 II-3: 998; LF249 II-2:1211; and LF262 II-4:
600). The size histograms of the remaining myelinated fibre
were shifted to the left; there was no fibre 48mmo f
diameter in any nerve. There were clusters of small
myelinated fibres that were abundant in LF135 II-1.
Hypomyelinated fibres with g-ratio 40.7 were present in
all nerves, especially in LF135 nerve; their proportion was
related to the amount of regenerating fibres. No alteration
in myelin sheath compaction was observed. There were
concentric Schwann cell formations in crescent shape,
usually around cluster of small myelinated fibres. We
consider these structures ‘pseudobulbs’ to distinguish them
from the typical onion bulb associated to the well
characterized demyelinating neuropathies (see Sevilla
et al., 2003 for details). The pathological picture was
summarized as a progressive axonal degeneration with very
active non-efficient axonal regeneration process.
Genetic analysis
Six different mutations in the GDAP1 gene have been found
in these families, including one missense (p.R282C), two
nonsense (p.Q163X and p.S194X), two frameshift muta-
tions (p.T288NfsX3 and p.P59AfsX4) and one splice-site
variant (c.311-1G4A). Pedigrees of families and associated
mutations are described in Fig. 1. All mutations had
previously been reported except a frameshift mutation,
produced by a deletion followed with an insertion in exon 2
of the GDAP1 gene (c.172_173delCTinsTTA, p.P59AfsX4)
creating a premature stop codon. Five families were found
to be compound heterozygous and the remaining three
families homozygous.
Discussion
All except one of the families with GDAP1 mutations
included in this series have been the subject of an extended
observation enabling us to keep an accurate record of the
clinical course of the disease. Two patients have died during
follow-up, one due to respiratory insufficiency and the
other to sudden death during sleep; both patients were
members of family LF249 and their clinical data have been
published previously (Sevilla et al., 2003). This event was
the main reason that encouraged us to examine the vocal
cords by means of flexible laryngoscopy and to plan a study
to evaluate respiratory function in these patients.
We found laryngeal and respiratory dysfunction in all
except one of our patients. Alterations of the voice started
to appear when the patients had a significant functional
disability, usually developing during adolescence. Four
patients presented bilateral paralysis of the vocal cords
and another four paralysis of the left vocal cord. None of
the patients presented isolated right vocal cord paralysis
and in two of the patients with bilateral paralysis we have
evidence that left cord paresis was detected in a previous
examination. The course of the disease was longer in
patients with bilateral vocal cord paralysis. All but one
patient (LF250 II-5) showed proximal weakness of upper
limbs, the only case with normal strength showed normal
mobility of vocal cords at examination, their neuropathy
started later and he is still able to walk at forty five.
Despite that vocal cord paresis is a prominent feature in
some forms of CMT, few studies have paid detailed attention
to vocal cord paralysis in these diseases. In DHMN-VIIA
(Young and Harper, 1980), symptoms started in second
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 decade of life, and atrophy of hand muscles preceded
involvement of the lower limbs. All but one affected
subjects developed unilateral or bilateral vocal cord
paralysis, the onset of dysphonia was variable and in some
cases preceded atrophy of the hand muscles. Although
dyspnoea on effort was present in two patients, screening
of diaphragm movement was normal. Pridmore et al.
(1992) found another family with similar characteristics
which was related to the former as proved by subsequent
molecular studies and genealogy investigations (McEntagart
et al., 2001).
In DHMN-VIIB (Puls et al., 2005), clinical phenotype
was characterized by bilateral vocal cord paralysis appearing
in adulthood followed by facial, hand, and finally distal leg
weakness. Laryngoscopy showed either a symmetrical deficit
reduction in vocal cord abduction or an abduction deficit
greater on the left side. However, phrenic nerve responses
were normal in all patients. The severity of the disease
manifestations in patients of the same age was similar.
Clinical findings of this family resembles our patients in
that vocal cord deficit was greater on the left than the right
side but differs in the progression of muscle involvement.
DHMN-VIIB follows a craneo–caudal pattern (laryngeal,
facial, upper and lower limbs), whereas GDAP1 neuropathy
follows the opposite pattern (lower limbs, upper limbs,
diaphragm and laryngeal muscles). In DHMN-VII types,
phrenic involvement has not been reported.
CMT2C is an autosomal dominant axonal form of
peroneal muscular atrophy with progressive muscle weak-
ness and atrophy of limbs, diaphragm, vocal cord, and
intercostals muscles with variable degrees of acral sensory
loss (Dyck et al., 1994; Lacy et al., 2001; Santoro et al.,
2002; McEntagart et al., 2005). Among affected persons, the
age at onset and clinical severity were variable. Voice
change was the initial symptom in several cases, being
atrophy of the hand muscles the second most reported
symptom. The clinical features of CMT2C and DHMN-
VIIA and B overlap considerably but are distinguished by
the presence of sensory involvement in CMT2C. Contrary
to our cases, vocal cord involvement in these three types
sometimes precedes the neuropathy and is not necessarily
related to its severity.
Vocal cord palsies and diaphragmatic weakness have also
been described in other varieties of CMT; three cases of
diaphragmatic weakness, and one of vocal cord palsy were
reported in the most severely affected patients of a large
CMT1A series (Thomas et al., 1997). Another case was
reported in one member of a CMT1 family associated with
a dominant heterozygous EGR2 mutation, developing vocal
cord palsy and dyspnoea several years after becoming
chairbound (Pareyson et al., 2000). In both types, the
clinical picture, like in our patients, was of a length related
neuropathy affecting the lower limbs to a greater extent
than the upper limbs. Other cases of CMT with vocal cord
paresis have been reported in patients who have not been
genetically typified. In these cases the vocal cord palsy was
usually associated to diaphragmatic weakness and appeared
in the latter stages of the disease (Johnson et al., 1981;
Tyson et al., 1997). Sulica et al. (2001) reported a patient
with CMT and episodic paralysis of both vocal cords who
was asymptomatic at the time of examination but had
presented episodes of dysphonia during the previous year.
They performed a review of the literature and concluded
that, in general, vocal cord paresis is well tolerated in
patients with CMT as only two cases had required
tracheotomy. This good tolerance was thought to be due
to the insidious course of the neuropathy, permitting
reinnervation and recovery of part of the function.
Table 4 shows a summary of the characteristics of
published cases with GDAP1 mutations and vocal cord
paresis (Azzedine et al., 2003; Boerkoel et al., 2003;
Stojkovic et al., 2004; Bouhouche et al., 2007a; Kabzinska
et al., 2007). Two siblings (Azzedine et al., 2003) developed
intermittent dysphonia, becoming permanent in one of
them after 10 years; in this patient, laryngoscopy revealed
paresis of the left vocal cord. In these reports, as well as in
our series, the features associated with vocal cord paresis
were: proximal muscle weakness, long history of the disease
and frequently diaphragmatic involvement. These patients
were of different ethnic origins and had different mutations
and phenotypes. As we can see in Tables 1 and 4, p.Q163X
and p.S194X are prevalent mutations in patients with vocal
cord palsy and GDAP1 neuropathy. In our series all
mutations except p.R282C were associated to vocal cord
involvement. The patient harbouring this mutation pro-
gressed with a less severe phenotype and without vocal cord
and diaphragm involvement. The p.R282C mutation has
been reported in two other families, one of Turkish and
one of Croatian origin (Ammar et al., 2003; Nelis et al.,
2002) and the clinical course in these patients was less
severe than usually seen in cases of GDAP1 neuropathy.
All the laryngeal muscles except for the cricothyroid
muscle are innervated by the recurrent laryngeal nerve, a
branch of the vagus. The path of the left recurrent laryngeal
nerve is longer than the right, leading us to suspect that the
vulnerability of this nerve in patients with CMT and
GDAP1 mutations is due to its length and not to genetic or
environmental factors. Paralysis in adduction is probably
due to the tensor action of the cricothyroid muscle which is
innervated by the superior laryngeal nerve, also a branch of
the vagus but shorter than the recurrent nerve, and it is
usually spared or less affected. In GDAP1 neuropathy,
paresis of the vocal cords probably represents a stage in the
neuropathy and may be an indicative parameter of the
severity of the disease. Dysphagia has been reported in a
patient with vocal cord paresis and severe weakness
(Boerkoel et al., 2003), this finding is probably due to
dysfunction of the pharyngeal branches of the vagus nerve,
whose path is shorter than laryngeal recurrent nerves. Other
cranial nerves apart from the vagus nerve may be affected,
such as the facial nerve: one of our patients presented
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 bilateral facial weakness, a finding reported in other cases
(Boerkoel et al., 2003).
The majority of our patients presented a severe form
of CMT, with a delay in the acquisition of motor functions or
with an onset of the disease around one year of age and
marked weakness of the proximal muscles during the
first decade of life. All the patients presented sensory loss
on physical examination, although neither subjective sensory
complaints nor sensory ataxia were a feature. The
clinical profile was quite similar to the description of the
Moroccan families reported by Bouhouche et al. (2007b)
who were homozygous for the GDAP1p.S194X mutation,
but the course in our cases was somewhat more severe.
In fact, in the second decade of their lives the majority
of the Moroccan patients were still able to walk with the aid of
a walking-stick whereas our cases were already in wheelchairs.
Dysphonia was not reported in any of the Moroccan
patients. All of them were examined before the age of 20
with the exception of a man of 38 years old, and flexible
laryngoscopy was not reported in any of them.
Moreover, vocal cord paresis may be overlooked during a
routine neurological evaluation. Three of our families are
compound heterozygotes for the Moroccan mutation
p.S194X and another mutation. As observed in the
Moroccan families, all our cases showed also an axonal
form of CMT.
Despite allelic heterogeneity, the natural history of the
disease and clinical phenotype of our patients were fairly
homogenous, except for LF250 II-5 proband. The molecular
pathology of this patient is different to the others. While
LF250 II-5 is homozygous for the missense p.R282C
mutation, the other patients were homozygous or compound
heterozygous for nonsense or frameshift mutations that
predict a truncated protein. GDAP1 is a protein located in the
outer mitochondrial membrane (Niemann et al., 2005) that
contains two GST domains and transmembrane domains.
Cell expression of truncated GDAP1 proteins with no
transmembrane and C-terminal domains (amino acids 320–
358) are misallocated in the cell cytoplasm and nucleus,
suggesting that these forms may be non functional (Pedrola
et al., 2005). By contrast, the p.R282C GDAP1 mutant protein
is correctly located in the mitochondria and induces
mitochondrial fission as GDAP1 wild-type (Pedrola et al.,
2005; Pedrola et al., 2008). It could be argued that the
presence of a non functional mutation may have a more
severe deleterious effect than the cell expression of a missense
mutation in the GDAP1 protein. Thus, in the case of LF250
II-5 proband, the deleterious effect of p.R282C mutations
on the nerve physiology could induce a milder clinical
phenotype.
All our patients except one presented a restrictive alteration
of respiratory function, elevation of the diaphragm on the
Table 4 Vocal cord paralysis in reported CMT patients with GDAP1gene mutations
Authors Onset Age/sex Ethnicity/
Mutation
CMT type Hoarseness
(years)/
Laryngoscopy
Respiratory
impairment
Functional
disability
Boerkoel et al. (2003) 2 years 34/F Japanese/
p.R120Q/
p.R120Q
Demyelinating Yes NR Proximal
weakness
Boerkoel et al. (2003) 0.5 year 61/M Costa Rican/
p.Q163X/
p.Q163X
Demyelinating Yes NR Proximal
weakness
Azzedine et al. (2003) 3 years 30/M Morocco
p.S194X/
p.R310Q
Axonal Y es, (20^30
years
intermittent)/
Left VC palsy
Yes
Diaphragm palsy
FVC 49%
W-B from
15 years
Azzedine et al. (2003) 3 years 26/F Morocco
p.S194X/
p.R310Q
Axonal Yes, episodic
2nd decade
No FVC 99% Crutch from
16 years
Stojkovic et al.(2004) DW 20 months 32/F French
p.I186fsX205/
p.I186fsX205
Axonal Early in life/
VC paresis
Dyspnoea MIP #
Diaphragm palsy
W-B from
25 years
Stojkovic et al. (2004) DW 20 months 33/F French
p.I186fsX205/
p.I186fsX205
Axonal Early in life/
VC paresis
Dyspnoea MIP #
Diaphragm palsy
W-B from
25 years
Bouhouche et al. (2007a) 1.5 years 19/F Morocco
p.P78L/
p.P78L
Mixed Yes NR W-B from
15 years
Bouhouche et al.( 2 0 0 7 a )51year 15/M Morocco p.P78L/
p.P78L
Mixed Yes NR Walked with cane
Kabzinska et al. (2007) 3.5 years 32/M Polish p.P153L/
p.P153L
Axonal Yes (29 years) NR W-B from 27 years
F=female; M=male; DW=delayed walking; W-B=wheelchair bound; NR=not reported.
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 chest X-ray, and a reduction of phrenic nerve CMAP,
demonstrating that the respiratory dysfunction was due to
muscle weakness. Global respiratory muscle strength is
measured using the MIP and MEP. The MIP was clearly
altered in three patients, two of whom presented a severe
reduction of the FVC and the other a mild reduction (71% of
the predicted value) but with a very significant paralysis of the
vocal cords with marked limitation of abduction that could
impede air entry. Four patients had normal or only slightly
altered MIP and MEP values despite a moderate reduction of
the FVC (50–75% of the predicted value). Preservation
of intercostals muscle function may explain this lack of
correlation between the FVC values and those of the MIP and
MEP. Similar findings have been reported in other patients
with weakness of the diaphragm and CMT (Laroche et al.,
1988; Hardie et al., 1990). Blood gases were normal in all
patients, demonstrating that there was no hypoventilation in
any of them. Four factors were associated with respiratory
dysfunction in our series. They were: proximal upper
extremity weakness, bilateral diaphragmatic alteration,
advanced age and obesity. The patient affected by all four
factors (LF262 II-4) had the most severe respiratory failure,
those patients affected by three of the four factors showed
moderate to severe respiratory dysfunction (LF20 II-3 and
LF80 II-1), and those affected by two of the factors had only
moderate dysfunction (LF249 II-2, LF20 II-4, LF135 II-1,
LF107 II-1 and LF14 II-7). Patient LF250 II-5 showed no
evidence of either respiratory dysfunction or upper limb
proximal weakness. Upper limb proximal weakness and
bilateral diaphragmatic paresis are the factors most clearly
predictive of respiratory involvement in our series; obesity
clearly played a role in determining the severity. Our findings
are in keeping with other studies that have shown that
proximal upper limb weakness and age are predictive of
abnormal pulmonary function (Nathanson et al., 1989;
Aboussouan et al., 2007). Sleep apnoea syndrome was present
in two patients. It was of the obstructive type in case LF249
II-2 due to severity the pharyngolaryngeal neuropathy while
in the other case it was of the central type associated with
obesity-hypoventilation syndrome. Although others studies
have found a correlation between sleep apnoea syndrome and
neuropathy severity in patients with CMT1 (Dematteis et al.,
2001; Dziewas et al., 2008), in our series it is not easy to
establish such a correlation because in all but one patient
functional disability is quite homogeneous.
Two members of a single family (LF249) died in their
fifth decade of life; both presented vocal cord paresis and
phrenic nerve dysfunction. One of them died due to
respiratory insufficiency secondary to recurrent infections
that could have been related to an acquired immunodefi-
ciency syndrome, although the weakness of the respiratory
muscles was probably a compounding factor. The sibling
died of sudden death, and it cannot be determined whether
vocal cord paresis could have precipitated the event. The
only living member of this family with the disease has
presented signs and symptoms of pudendal nerve
involvement in recent years, demonstrating that shorter
nerves are affected as the disease progresses. Weakness of
pelvic floor muscles has also been reported in two severe
CMT1A cases (Thomas et al., 1997).
In conclusion, patients with CMT and mutations of
GDAP1 have a length dependent neuropathy that causes
progressive muscle weakness, affecting the more distal
muscles of the limbs initially and finally involving the
cranial nerves and respiratory muscles. The earlier involve-
ment of the left recurrent laryngeal nerve compared to the
nerve on the right side supports this conclusion. Vocal cord
paralysis and respiratory insufficiency can lead to aspiration
and bronchopneumonia, decreasing the life expectancy of
these patients. It is therefore important to specifically
investigate patients with CMT due to GDAP1 mutations for
evidence of laryngeal and respiratory dysfunction.
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